myelosuppressive effects
骨髓抑制作用
myelosuppressive potential
骨髓抑制潛能
myelosuppressive risk
骨髓抑制風險
myelosuppressive state
骨髓抑制狀態
the patient experienced severe myelosuppressive effects after the bone marrow transplant.
骨髓移植後，患者出現了嚴重的骨髓抑制作用。
we need to monitor for myelosuppressive potential with this new chemotherapy regimen.
我們需要監測這種新化療方案的骨髓抑制潛在風險。
myelosuppressive drugs can significantly reduce white blood cell counts.
骨髓抑制藥物會顯著降低白細胞數量。
the physician was concerned about the myelosuppressive nature of the medication.
醫生對這種藥物的骨髓抑制特性感到擔憂。
neutropenia is a common side effect of myelosuppressive therapies.
中性粒細胞減少是骨髓抑制療法的常見副作用。
careful dose adjustments are necessary to mitigate myelosuppressive risks.
為減輕骨髓抑制風險，需要仔細調整劑量。
the study investigated the myelosuppressive impact of the experimental compound.
該研究調查了實驗性化合物的骨髓抑制影響。
patients receiving myelosuppressive treatment require frequent blood tests.
接受骨髓抑制治療的患者需要頻繁進行血液檢查。
we considered alternative therapies to avoid further myelosuppressive complications.
我們考慮了替代療法以避免進一步的骨髓抑制併發症。
the drug's mechanism of action includes a myelosuppressive component.
這種藥物的作用機制包括骨髓抑制成分。
early detection of myelosuppression is crucial for patient safety.
早期發現骨髓抑制對患者安全至關重要。
myelosuppressive effects
骨髓抑制作用
myelosuppressive potential
骨髓抑制潛能
myelosuppressive risk
骨髓抑制風險
myelosuppressive state
骨髓抑制狀態
the patient experienced severe myelosuppressive effects after the bone marrow transplant.
骨髓移植後，患者出現了嚴重的骨髓抑制作用。
we need to monitor for myelosuppressive potential with this new chemotherapy regimen.
我們需要監測這種新化療方案的骨髓抑制潛在風險。
myelosuppressive drugs can significantly reduce white blood cell counts.
骨髓抑制藥物會顯著降低白細胞數量。
the physician was concerned about the myelosuppressive nature of the medication.
醫生對這種藥物的骨髓抑制特性感到擔憂。
neutropenia is a common side effect of myelosuppressive therapies.
中性粒細胞減少是骨髓抑制療法的常見副作用。
careful dose adjustments are necessary to mitigate myelosuppressive risks.
為減輕骨髓抑制風險，需要仔細調整劑量。
the study investigated the myelosuppressive impact of the experimental compound.
該研究調查了實驗性化合物的骨髓抑制影響。
patients receiving myelosuppressive treatment require frequent blood tests.
接受骨髓抑制治療的患者需要頻繁進行血液檢查。
we considered alternative therapies to avoid further myelosuppressive complications.
我們考慮了替代療法以避免進一步的骨髓抑制併發症。
the drug's mechanism of action includes a myelosuppressive component.
這種藥物的作用機制包括骨髓抑制成分。
early detection of myelosuppression is crucial for patient safety.
早期發現骨髓抑制對患者安全至關重要。
探索常見搜尋詞彙